AACR is coming in April. See you at $50 in the next few yrs.
Imagine a company that fully owns 9+ drug candidates backed by patents. Imagine that the trials to date have had very good data. Imagine the company is so undervalued that big time investors gave it over $90 million with basically no discount. Well, it's not your imagination. It's a leader in precision targeted therapies. A company called Celldex! See you at $50 within 3 years folks. That is my strong opinion
I doubt it's going to take 3 years to get to 50. In three years Celldex will have not one, but two very effective treatments in for approval, new indication studies ongoing in these and several others from the pipeline in phase III and host more coming forward. The two lead treatments will be $100K per course of therapy in easily identified populations with unmet medical need. More like $80-90/share in 3 years time. I think $25 is reasonable valuation by the end of this year.